Trials / Sponsors / Navire Pharma Inc., a BridgeBio company
Navire Pharma Inc., a BridgeBio company
Industry · 3 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Terminated | SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With Non Small Cell Lung Cancer, Solid Tumor | Phase 1 | 2022-10-20 |
| Terminated | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mu Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC | Phase 1 | 2022-07-06 |
| Terminated | First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors Tumor, Solid | Phase 1 | 2020-11-12 |